HCP, Inc. (NYSE:HCP) Director R Kent Griffin, Jr. bought 21,100 shares of HCP stock in a transaction that occurred on Monday, May 14th. The shares were acquired at an average price of $23.80 per share, for a total transaction of $502,180.00. Following the completion of the transaction, the director now directly owns 30,575 shares of the company’s stock, valued at approximately $727,685. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

HCP stock opened at $23.37 on Wednesday. The stock has a market capitalization of $11.18 billion, a PE ratio of 11.98, a PEG ratio of 5.99 and a beta of 0.24. The company has a current ratio of 0.15, a quick ratio of 0.15 and a debt-to-equity ratio of 1.25. HCP, Inc. has a 12 month low of $23.30 and a 12 month high of $23.70.

HCP (NYSE:HCP) last released its quarterly earnings data on Thursday, May 3rd. The real estate investment trust reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.38). The firm had revenue of $479.20 million during the quarter, compared to analysts’ expectations of $452.86 million. HCP had a negative return on equity of 0.13% and a negative net margin of 0.41%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.51 earnings per share. equities analysts forecast that HCP, Inc. will post 1.81 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 22nd. Investors of record on Monday, May 7th will be issued a dividend of $0.37 per share. The ex-dividend date of this dividend is Friday, May 4th. This represents a $1.48 annualized dividend and a dividend yield of 6.33%. HCP’s payout ratio is currently 75.90%.

Several research firms recently weighed in on HCP. ValuEngine downgraded HCP from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. BMO Capital Markets reiterated a “hold” rating and set a $25.00 target price on shares of HCP in a research report on Thursday, May 3rd. Wells Fargo reduced their target price on HCP from $31.00 to $27.00 and set a “market perform” rating on the stock in a research report on Tuesday, March 20th. Jefferies Group reiterated a “hold” rating and set a $26.00 target price on shares of HCP in a research report on Tuesday, February 13th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $27.00 target price (down from $29.00) on shares of HCP in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $27.15.

Large investors have recently made changes to their positions in the stock. Vestpro Financial Partners Inc. dba CPF Texas purchased a new stake in shares of HCP during the 4th quarter valued at about $103,000. Archford Capital Strategies LLC purchased a new stake in shares of HCP during the 1st quarter valued at about $167,000. Advisor Partners LLC purchased a new stake in shares of HCP during the 1st quarter valued at about $228,000. Ellington Management Group LLC purchased a new stake in shares of HCP during the 4th quarter valued at about $232,000. Finally, Bank of Hawaii purchased a new stake in shares of HCP during the 1st quarter valued at about $238,000. Institutional investors and hedge funds own 90.46% of the company’s stock.

HCP Company Profile

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests primarily in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.